An intravenous bispecific, bivalent T-cell–engaging antibody that binds CD3 on T cells and the MAGE-A4 peptide presented by HLA-A*02:01 on tumor cells to redirect T-cell cytotoxicity.
An intravenous bispecific, bivalent antibody that binds CD3 on T cells and the MAGE-A4 peptide presented by HLA-A*02:01 on tumor cells, cross-linking T cells to cancer cells. This engagement activates TCR/CD3 signaling, induces cytokine release, and redirects cytotoxic T-cell killing of MAGE-A4–expressing tumor cells.
The bispecific T-cell engager binds the MAGE-A4 peptide–HLA-A*02:01 complex on tumor cells and CD3 on T cells, cross-linking and activating T cells to release perforin/granzymes and induce apoptosis of the target-expressing cells.
Izalontamab brengitecan (BMS-986507), a bispecific antibody–drug conjugate targeting EGFR and HER3 that releases a camptothecin/topoisomerase I inhibitor payload to induce DNA damage and tumor cell death.
Bispecific ADC targeting EGFR and HER3; upon receptor binding and internalization, it releases a camptothecin/topoisomerase I–inhibitor payload that induces DNA damage (via Topo I inhibition) leading to tumor cell death, with potential bystander effect.
The bispecific ADC binds EGFR on tumor cells, is internalized, and releases a camptothecin/topoisomerase I–inhibitor payload that induces DNA damage leading to cell death (with potential bystander effect).
Izalontamab brengitecan (BMS-986507), a bispecific antibody–drug conjugate targeting EGFR and HER3 that releases a camptothecin/topoisomerase I inhibitor payload to induce DNA damage and tumor cell death.
Bispecific ADC targeting EGFR and HER3; upon receptor binding and internalization, it releases a camptothecin/topoisomerase I–inhibitor payload that induces DNA damage (via Topo I inhibition) leading to tumor cell death, with potential bystander effect.
The bispecific ADC binds HER3 on tumor cells, is internalized, and releases a camptothecin/topoisomerase I inhibitor payload that induces DNA damage, directly killing HER3-expressing cells (with potential bystander effect).
An investigational IgE-class monoclonal antibody targeting folate receptor‑alpha (FRα). It binds FRα on tumor cells and engages FcεRI-bearing immune effector cells to induce ADCC/ADCP and degranulation against FRα-positive ovarian cancer cells.
MOv18 IgE is an IgE-class monoclonal antibody that binds folate receptor‑alpha (FRα) on tumor cells and engages FcεRI-bearing effector cells (and CD23), triggering ADCC/ADCP and degranulation to kill FRα‑positive ovarian cancer cells.
MOv18 IgE binds FRα on tumor cells and engages FcεRI/CD23 on immune effector cells, inducing ADCC/ADCP and cytotoxic degranulation that kills FRα-positive cells.
Type II anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity and induces direct B-cell death.
Glycoengineered humanized type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells; enhanced Fc gamma RIII affinity increases antibody-dependent cellular cytotoxicity and it induces direct, caspase-independent B-cell death, depleting malignant CD20-positive B cells.
Binds CD20 on B cells and causes killing via Fc gamma RIII–mediated antibody-dependent cellular cytotoxicity; also induces direct, caspase-independent B-cell death (with some complement-mediated lysis).